Stereotactic body radiotherapy (SBRT) alone achieves a 69.7% pooled 1- or 2-year systemic therapy-free survival rate across cancer types, with the highest rates seen in renal cell and prostate cancers ...
Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma) Between March 19, 2019, and February 13, 2023, 41 ...
Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study ...
—Building off of earlier findings, researchers sought to determine rates of neoadjuvant systemic therapy (NST) among U.S. women with cT1–2 N0 M0 HER2-positive breast cancer and identify factors ...
Despite major advances in targeted therapies, immunotherapies, and combination regimens, therapy resistance remains a central barrier to durable cancer ...
If you have seen the movie Inside Out, you might already be familiar with the concept of internal family systems, or IFS, therapy. Developed by Dr. Richard Schwartz in the 1980s, IFS is a model of ...
“The FDA approval of Breyanzi for relapsed or refractory marginal zone lymphoma further solidifies it as the leading CD19-directed CAR T cell therapy covering the broadest range of B-cell malignancies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results